Earn Rewards with Apoquel
Apoquel has been prescribed for over 13 million dogs1 and is #1 in pet owner and vet satisfaction for oral medications for allergic dermatitis in dogs.2,3*
Rewards That Help Pay for Future Vet Care
| Tablet Count | Reward Points | Rewards Value |
|---|---|---|
| 30 | 90 | 9 |
| 45 | 140 | 14 |
| 60 | 180 | 18 |
| 100 | 350 | 35 |
| 250 | 800 | 80 |
IMPORTANT SAFETY INFORMATION: See full Apoquel Tablet and Apoquel Chewable Prescribing Information. Do not use Apoquel or Apoquel Chewable in dogs less than 12 months of age or those with serious infections. Apoquel and Apoquel Chewable may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre- existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post- approval. Apoquel and Apoquel Chewable have not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. Apoquel and Apoquel Chewable have been used safely with many common medications including parasiticides, antibiotics and vaccines.
INDICATIONS: Control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
*Vets, n=250; pet owners, n=491.
References:
- Data on file, ZMR: Kynetec PetTrak – Pets Since Launch December 2022, Zoetis Inc.
- Data on file, APOQUEL/CYTOPOINT Pet Owner Tracker Wave 11, 2022, Zoetis Inc.
- Data on file, APOQUEL/CYTOPOINT Vet Tracker Wave 17, 2022, Zoetis Inc.
- Gonzales AJ, Bowman JW, Fici G, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317-324.
APQ-00679R11 | ZPR-00175R2
